Apogee Therapeutics, Inc. 8-K

What Happened
Apogee Therapeutics, Inc. (APGE) filed an 8‑K reporting that on May 26, 2026 it entered a Revenue Participation Right Purchase and Sale Agreement with Annapurna Aggregator L.P., an affiliate of funds managed by Blackstone Life Sciences (BXLS). BXLS paid $100.0 million at closing (Tranche 1 Funding) for tiered rights to receive future revenue‑share payments tied to worldwide net sales of Apogee’s anti‑IL‑13 antibody zumilokibart (APG777). BXLS may fund up to three additional tranches — $100M (Tranche 2), $200M (Tranche 3) and an optional $250M–$400M (Tranche 4) — contingent on trial enrollment, positive Phase 3 data, and FDA approval timing.

Key Details

• Effective date: May 26, 2026; press release issued May 27, 2026.
• Upfront payment: $100.0 million (Tranche 1). Potential additional funding: $100M (Tranche 2), $200M (Tranche 3), and $250M–$400M (Tranche 4) — meaning up to $700M additional after the $100M upfront (total potential funding up to $800M).
• Revenue share mechanics: Base Revenue Percentage shown after Tranche 1 is 0.9375% for annual net sales up to $5B (Tier 1); a Tranche 4 Revenue Percentage of 2.50% also applies for Tier 1 when Tranche 4 is funded, giving the table’s listed maximum of 3.4375% for Tier 1. For annual sales between $5B and $8B the base rate is 0.25% (no Tranche 4 percentage). The Base Revenue Percentage doubles upon Tranche 2 funding and doubles again upon Tranche 3 funding per the agreement. Tranche 4 payments are capped: $1.0B aggregate Tranche 4‑related payments, after which the Tranche 4 percentage for Tier 1 falls to 0%.
• Term and security: Revenue Share Payments begin on first commercial sale and run until the 15th anniversary of FDA approval receipt; Apogee granted BXLS a backup security interest in the revenue participation right, related revenue payments and zumilokibart‑related IP/product rights (subject to termination on specified events).
• Change‑of‑control and buy‑back: The agreement includes specified change‑of‑control payments (creditable against future revenue shares) and gives Apogee options to pay to buy down future revenue shares under defined windows. The parties also agreed to negotiate in good faith a potential debt financing of up to $500M.

Why It Matters
This transaction provides Apogee with $100M of immediate, non‑dilutive capital and the potential for substantial milestone‑driven financing tied to clinical and regulatory progress for zumilokibart. For investors, the deal reduces near‑term cash needs without issuing equity, but it creates future obligations: a portion of product sales (measured in small percentage points per the tiers) will be paid to BXLS for up to 15 years after approval, and Apogee granted backup security interests to support those rights. The actual financial impact will depend on whether additional tranches are funded (trial enrollment, positive Phase 3 readouts, FDA timing) and on future product sales levels.